psg2.hivconsv dna vaccine
Vaccineexperimental
Clinical trial activity
3 trials · 9 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2010 (NCT01151319)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Human immunodeficiency virusImmunity, active
Human immunodeficiency virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- psg2.hivconsv
- psg2.hivconsv dna
- psg2.hivconsv dna vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02099994 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2014 | European and Developing Countries Clinical Trials Partnership (EDCTP), Ichor Medical Systems Incorporated, International AIDS Vaccine Initiative, Karolinska Institute, University of Nairobi, University of Oxford |
| NCT02425241 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2013 | GlaxoSmithKline, Medical Research Council, University of London, University of Oxford |
| NCT01151319 | Phase 1 | Oct 1, 2010 | University of Oxford |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (9)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Oxford | Academic/Hospital | 3 | 2 | 2 | 2010 |
| European and Developing Countries Clinical Trials Partnership (EDCTP) | Academic/Hospital | 1 | 0 | 1 | 2014 |
| GlaxoSmithKline | For profit | 1 | 0 | 1 | 2013 |
| Ichor Medical Systems Incorporated | For profit | 1 | 0 | 1 | 2014 |
| International AIDS Vaccine Initiative | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Karolinska Institute | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Medical Research Council | Government | 1 | 0 | 1 | 2013 |
| University of London | Academic/Hospital | 1 | 1 | 1 | 2013 |
| University of Nairobi | Academic/Hospital | 1 | 0 | 1 | 2014 |
9 organizations
Page 1 / 1